Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€169.95

€169.95

2.230%
3.7
2.230%
€172.00

€172.00

 
11:10 / Tradegate WKN: 659990 / Symbol: MKGAF / Name: Merck / Stock / Pharmaceuticals / Large Cap /
Latest predictions
€190.00
01.08.24
1.01%
buy
02.04.24
7.12%
buy
€172.00
30.03.24
5.09%
buy
17.03.24
9.96%
buy
€120.00
15.02.24
10.60%
Your prediction

Merck KGaA Stock

There is an upward development for Merck KGaA compared to yesterday, with an increase of €3.70 (2.230%).
Currently there is a rather positive sentiment for Merck KGaA with 4 Buy predictions and 1 Sell predictions.
With a target price of 172 € there is a slightly positive potential of 1.21% for Merck KGaA compared to the current price of 169.95 €.
Our community identified positive and negative aspects for Merck KGaA stock for the coming years. 1 users see the criterium "Return on equity" as a plus for the Merck KGaA stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.

Pros and Cons of Merck KGaA in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Merck KGaA vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Merck KGaA 2.230% -2.550% -0.776% 3.133% 15.491% -15.416% 67.625%
Bayer AG 2.710% 2.592% -4.123% -42.753% -17.073% -38.501% -58.038%
Elanco Animal Health Inc. -1.330% -0.850% -1.597% 18.297% -3.402% -52.733% -
Johnson & Johnson -0.410% 0.013% 3.457% -1.566% 5.664% 6.552% 26.561%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.

Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.

Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.

Comments

Buy Merck KGaA
Show more

Buy Merck KGaA
Show more

Sell Merck KGaA
Show more

News

Where Will Merck Stock Be in 5 Years?: https://g.foolcdn.com/editorial/images/790399/merck-stock-bullish-outlook-2024.jpg
Where Will Merck Stock Be in 5 Years?

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in this pharmaceutical giant's success is its Keytruda immunotherapy drug

Why Summit Therapeutics Rocketed Over 60% Today: https://g.foolcdn.com/editorial/images/790179/dna-genetic-sequencing-biotech.jpg
Why Summit Therapeutics Rocketed Over 60% Today

Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT.

The biotech firm released the results of a Phase III study on

Is Merck Stock Undervalued After Its Colossal Earnings Growth?: https://www.marketbeat.com/logos/articles/med_20240906082957_is-merck-stock-undervalued-after-its-colossal-earn.jpg